Novel glycosylation zinc(II)–cryptolepine complexes perturb mitophagy pathways and trigger cancer cell apoptosis and autophagy in SK-OV-3/DDP cells
Zhen Zhou,Ling-Qi Du,Xiao-Mei Huang,Li-Gang Zhu,Qiao-Chang Wei,Qi-Pin Qin,Hedong Bian
DOI: https://doi.org/10.1016/j.ejmech.2022.114743
IF: 7.088
2022-09-09
European Journal of Medicinal Chemistry
Abstract:With the aim of shedding some light on the mechanism of action of zinc(II) complexes in antiproliferative processes and molecular signaling pathways, three novel glycosylated zinc(II)–cryptolepine complexes, i.e., [Zn(QA1)Cl 2 ] ( Zn(QA1) ), [Zn(QA2)Cl 2 ] ( Zn(QA2) ), and [Zn(QA3)Cl 2 ] ( Zn(QA3) ), were prepared by conjugating a glucose moiety with cryptolepine, followed by complexation of the resulting glycosylated cryptolepine compounds N -((1-(2-morpholinoethyl)-1H-1,2,3-triazol-4-yl)methyl)-benzofuro[3,2-b]quinolin-11-amine ( QA1 ), 2-(4-((benzofuro[3,2-b]quinolin-11-ylamino)methyl)-1H-1,2,3-triazol-1-yl)ethan-1-ol ( QA2 ), and (2S,3S,4R,5R,6S)-2-(4-((benzofuro[3,2-b]quinolin-11-ylamino)-methyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol ( QA3 ) with zinc(II), and their anticancer activity was evaluated. In MTT assays, Zn(QA1) – Zn(QA3) were more active against cisplatin-resistant ovarian SK-OV-3/DDP cancer cells (SK-OV-3cis) than ZnCl 2 and the QA1 – QA3 ligands, with IC 50 values of 1.81 ± 0.50, 2.92 ± 0.32, and 1.01 ± 0.11 μM, respectively. Complexation of glycosylated cryptolepine QA3 with zinc(II) increased the antiproliferative activity of the ligand, suggesting that Zn(QA3) could act as a chaperone to deliver the active ligand intracellularly, in contrast with other cryptolepine metal complexes previously reported. In vivo and in vitro investigations suggested that Zn(QA3) exhibited enhanced anticancer activity with treatment effects comparable to those of the clinical drug cisplatin. Furthermore, Zn(QA1) – Zn(QA3) triggered SK-OV-3cis cell apoptosis through mitophagy pathways in the order Zn(QA1) > Zn(QA1) > Zn(QA2) . These results demonstrate the potential of glycosylated zinc(II)–cryptolepine complexes for the development of chemotherapy drugs against cisplatin-resistant SK-OV-3cis cells.
chemistry, medicinal